To evaluate the Efficacy of magnesium sulfate in laryngoscopy

To evaluate the Efficacy of magnesium sulfate in feasibility of direct laryngoscopy in difficult exposure patients, a non-randomized trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210712051865N1

Enrollment

Registered

2021-09-08

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

difficult exposure direct laryngoscopy.

Interventions

Intervention group: Slow intravenous infusion (in 1 minute by microset) of magnesium sulfate(50 mg/kg in 50 cc normal saline) and after 5 minutes re-evaluate the laryngeal difficulty exposure and reco

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with difficult airway according to cormack-Lehane criteria

Exclusion criteria

Exclusion criteria: cardiovascular diseases and arrhythmia and any underlying medical condition that contraindicated to magnesium sulfate using according to anesthesiologist evaluation

Design outcomes

Primary

Measure	Time frame
Laryngeal exposure. Timepoint: Before intervention, After intervention. Method of measurement: According to Cormack-Lehane criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactkamyar iravani

Shiraz University of Medical Sciences

iravanika@sums.ac.ir0091716291478

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026